Drug Profile
BOS 342
Alternative Names: BOS-342; PRS-342Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Pieris
- Developer Boston Pharmaceuticals; Pieris Pharmaceuticals
- Class Antibodies; Antineoplastics; Immunotherapies; Lipocalins; Recombinant fusion proteins
- Mechanism of Action CD137 antigen agonists; Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Liver cancer
- No development reported Cancer
Most Recent Events
- 11 Sep 2023 Phase-I clinical trials in Liver cancer (unspecified route) before September 2023 (Boston Pharmaceuticals pipeline, September 2023)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 29 Mar 2023 Boston Pharmaceuticals plans a phase I trial in 2023